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Abstract
Background: We determined antibodies to the pandemic influenza A (H1N1) 2009 virus in children to assess: the incidence
of (H1N1) 2009 infections in the 2009/2010 season in Germany, the proportion of subclinical infections and to compare
titers in vaccinated and infected children.
Methodology/Principal Findings: Eight pediatric hospitals distributed over Germany prospectively provided sera from
in- or outpatients aged 1 to 17 years from April 1st to July 31st 2010. Vaccination history, recall of infections and sociodemo-
graphic factors were ascertained. Antibody titers were measured with a sensitive and specific in-house hemagglutination
inhibition test (HIT) and compared to age-matched sera collected during 6 months before the onset of the pandemic in
Germany. We analyzed 1420 post-pandemic and 300 pre-pandemic sera. Among unvaccinated children aged 1–4 and 5–17
years the prevalence of HI titers ($1:10) was 27.1% (95% CI: 23.5–31.3) and 53.5% (95% CI: 50.9–56.2) compared to 1.7% and
5.5%, respectively, for pre-pandemic sera, accounting for a serologically determined incidence of influenza A (H1N1) 2009
during the season 2009/2010 of 25,4% (95% CI : 19.3–30.5) in children aged 1–4 years and 48.0% (95% CI: 42.6–52.0) in 5–17
year old children. Of children with HI titers $1:10, 25.5% (95% CI: 22.5–28.8) reported no history of any infectious disease
since June 2009. Among vaccinated children, 92% (95%-CI: 87.0–96.6) of the 5–17 year old but only 47.8% (95%-CI: 33.5–
66.5) of the 1–4 year old children exhibited HI titers against influenza A virus (H1N1) 2009.
Conclusion: Serologically determined incidence of influenza A (H1N1) 2009 infections in children indicates high infection
rates with older children (5–17 years) infected twice as often as younger children. In about a quarter of the children with HI
titers after the season 2009/2010 subclinical infections must be assumed. Low HI titers in young children after vaccination
with the AS03B-adjuvanted split virion vaccine need further scrutiny.
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Introduction
In Germany, a total of approximately 223,000 laboratory-
confirmed symptomatic cases of pandemic influenza A (H1N1)
2009 infections have been notified from April 1st 2009 until March
31st 2010, accounting for a cumulative incidence of 272 per
100,000. Extrapolation from the 78% of notifications with age
information yields an incidence of 468 and 1,110 per 100,000 in age
groups 1 to 4 years and 5 to 17 years, respectively. Themain wave of
the pandemic occurred in weeks 43 to 51 of 2009 (unpublished data,
Robert Koch-Institute, Berlin, Germany).
Vaccination with a monovalent AS03B-adjuvanted H1N1-
vaccine (PandemrixH, GSK Pharma GmbH, Munich, Germany)
was offered for persons at risk in Germany as of week 44, 2009.
For adults and adolescents$14 years, ultimate vaccination coverage
has been estimated at ,8% on the basis of population-wide
telephone surveys [1]. Data on vaccination coverage for ,14 year
old children are not available.
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Seroprevalence studies of antibodies against A (H1N1) 2009
performed after the end of the 2009/2010 influenza season allow
for a much better estimation of the cumulative incidence of
pandemic A (H1N1) 2009 infections than case surveillance data if
corrected for vaccination status [2]. Such data also allow to assess
the current proportion of individuals with at least partial
protection against A (H1N1) 2009. The proportion of subclinical
infections can be estimated if a history of symptomatic infections is
documented.
Seroprevalence studies in children are of particular interest
since children are supposed to be the driving force of the influenza
pandemic [2–5]. Although several seroprevalence studies of A
(H1N1) 2009 antibodies have been published [6] there are few
studies which include children [2,7,8] and only one also con-
sidering vaccination and flu-like disease history as well [7]. No
study has compared antibodies against A (H1N1) 2009 after
confirmed clinical disease and vaccination with pandemic vaccine
in children.
We performed a multi-centre seroprevalence study on children
in Germany 1) to assess the incidence of A (H1N1) 2009 infections
in the 2009/2010 season, 2) to identify the proportion of sub-
clinical A (H1N1) 2009 infections, and 3) to compare HI antibody
titers in vaccinated children and in children after natural infection.
Results
Study population
1555 serum samples and 1511 questionnaires were collected.
Fourteen hemolytic sera could not be analyzed and 52 question-
naires were excluded because essential data were missing or
children were outside age limits. Merging of the remaining 1541
sera and 1459 questionnaires resulted in 1420 cases, with 373
children (26.3%) 1 to 4 years and 1047 children (73.7%) 5 to 17
years (see table 1). This corresponds to the overall distribution of
these age groups in Germany (1–4: 21.2%; 5–17: 78.8%) [9]. The
8 participating hospitals were distributed nationwide.
In the total sample boys and girls were evenly distributed.
84.1% of the children attended school or kindergarten. 70.5% of
all children reported a history of one or more infectious disease
episodes since June 2009. Influenza A (H1N1) 2009 was suspected
by a physician in 97 children (6.8%) and was virologically
diagnosed in 25 children (1.8%). Vaccination against seasonal
influenza in 2009/2010 or in previous years was reported in 15.7%
of all children. Vaccination against influenza A (H1N1) 2009 was
reported for 101 of the 1420 children (7.1%).
Hemagglutination inhibition test results - unvaccinated
children
Pre-pandemic (control) sera. The pre- and post-pandemic
HI titers and the incidence estimates for A (H1N1) 2009 infection
based on the difference between post- and pre-pandemic titers are
depicted in table 2.
Of the 300 control sera only 2 (1.7%) children ,5 years had
detectable antibodies in HIT (one child 1:10 and the second child
1:40). In the older age group 10 HIT-positive children were
detected (5.5%) including one titer of 1:80 (table 2). To analyze
whether these pre-pandemic titers corresponded to high antibody
titers against the most recent seasonal influenza A virus (A/
Brisbane/59/2007(H1N1)) we tested the sera which were positive
for antibodies against the pandemic A (H1N1) 2009 also for
Table 1. Characteristics of the post-pandemic samples.
Variable Subcategory
Not vaccinated
against A(H1N1)2009
Vaccinated against
A(H1N1)2009
Unknown vaccination
status against A(H1N1)2009 Total
N=1307 N=101 N=12 N=1420
n (column%) n (column%) n (column%) n (column%)
Age 1–4 years 347 (26.6) 23 (22.8) 3 (25.0) 373 (26.3)
5–17 years 960 (73.4) 78 (77.2) 9 (75.0) 1047 (73.7)
Sex Male 610 (46.7) 60 (59.4) 3 (25.0) 673 (47.4)
Female 675 (51.6) 40 (39.6) 9 (75.0) 724 (51.0)
Missing values 22 (1.7) 1 (1.0) 0 (0.0) 23 (1.6)
(Pre-)school attendance Yes 1097 (83.9) 89 (88.1) 8 (66.7) 1194 (84.1)
No 201 (15.4) 11 (10.9) 4 (33.3) 216 (15.2)
Missing values 9 (0.7) 1 (1.0) 0 (0.0) 10 (0.7)
History of infections No infection 374 (28.6) 19 (18.8) 3 (25.0) 396 (27.9)
.= 1 infection 914 (69.9) 78 (77.2) 9 (75.0) 1001 (70.5)
Missing values 19 (1.5) 4 (4.0) 0 (0.0) 23 (1.6)
Diagnosis of
A(H1N1) 2009
As suspected by physician 91 (7.0) 6 (5.9) 0 (0.0) 97 (6.8)
Lab-confirmed 25 (1.9) 0 (0.0) 0 (0.0) 25 (1.8)
No diagnosis 1030 (78.8) 80 (79.2) 10 (83.3) 1120 (78.9)
Missing values 161 (12.3) 15 (14.9) 2 (16.7) 178 (12.5)
Seasonal vaccine* Yes 176 (13.5) 43 (42.6) 4 (33.3) 223 (15.7)
No 1109 (84.8) 53 (52.5) 3 (25.0) 1165 (82.0)
Missing values 22 (1.7) 5 (4.9) 5 (41.7) 32 (2.3)
*children having been vaccinated against the seasonal influenza.
doi:10.1371/journal.pone.0023955.t001
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antibodies against this seasonal influenza virus. Four of the 12
children exhibiting antibodies against the pandemic A (H1N1)
2009 were negative for antibodies against the seasonal influenza
A virus (geometric mean titer 1:27). By testing additional 96
pre-pandemic sera for antibodies against the seasonal H1N1 virus
we found 48.9% positive (geometric mean titer 1:29) and no
association between pandemic and seasonal H1N1 titers (Spear-
man correlation coefficient 0.068, p-value 0.51).
Post-pandemic sera. Of 1307 children not vaccinated with
PandemrixH, HI titers of 1:10 or above were detectable in 607
(46.5%, 95% CI: 44.3–48.8). This percentage was lower for
children aged 1 to 4 years (27.1%, 95% CI: 23.5–31.3) and higher
for children aged 5 to 17 years (53.5%, 95% CI: 50.9–56.2),
p-value,0.0001 (figure 1 and table 2), with no difference between
boys and girls.
Logistic regression revealed a higher probability of detectable
HI titers by higher age and an influenza A (H1N1) 2009 infection
suspected by a physician or diagnosed by virological testing.
Except for a lower proportion of children with any detectable HI
titers in one center (Berlin) we observed no significant regional
variability. School or kindergarten attendance was not associated
with HI titers.
More than 40% of the children (13.7%+30.3%= 44.0%;
95%-CI: 39.5–48.9) who had reported no infection since June
2009 had HI titers of $1:10. In contrast all 25 children with
virologically proven A (H1N1) 2009 infection exhibited a positive
HI titer with 80% $1:40. Of the children with HI titers $1:10
25.5% (95% CI: 22.5–28.8) reported no history of any infectious
disease since June 2009 (table 3: (91+41)/(41+95+23+5+91+198+
45+20)).
Table 2. Pre-and post-pandemic hemagglutination inhibition titers (HIT) $1:10 and $1:40 for non-vaccinated children aged 1 to
17 years.
HIT Age-group Pre-pandemic controls Post-pandemic samples Difference: post – pre
n/N (%) n/N (%) (%)
95%CI Lower
Limit (%)
95%CI Upper
Limit (%)
.= 1:10 1–4 2/119 1.7 94/347 27.1 25.4 19.3 30.5
5–17 10/181 5.5 514/960 53.5 48.0 42.6 52.0
all 12/300 4.0 607/1307 46.5 42.4 38.5 45.6
.= 1:40 1–4 1/119 0.8 80/347 23.1 22.2 16.6 27.0
5–17 4/181 2.2 330/960 34.4 32.2 27.7 35.5
all 5/300 1.7 410/1307 31.4 29.7 26.4 32.4
CI = Confidence Interval.
doi:10.1371/journal.pone.0023955.t002
Figure 1. Reverse cumulative distribution curves of hemagglutination inhibition titers for antibodies against influenza A (H1N1)
2009 virus for different strata. Post-pandemic children not vaccinated against influenza A (H1N1) 2009 aged 1–17, thereof 347 aged 1–4 and 960
aged 5–17 were tested and in addition 300 pre-pandemic controls and 101 children vaccinated against influenza A (H1N1) 2009. Children aged 1–4
exhibit lower titers compared to children aged 5–17 and all post-pandemic cases. Titers of pre-pandemic children aged 1–17 are distinctly lower.
Children vaccinated against A (H1N1) 2009 exhibit higher titers compared to post-pandemic children having been infected with A (H1N1).
doi:10.1371/journal.pone.0023955.g001
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Hemagglutination inhibition test results – vaccinated
children and children after laboratory-confirmed
influenza A (H1N1) 2009 infection
All 6 children 1 to 4 years old (100%, 95% CI: 61.0–100) with a
history of laboratory-confirmed A (H1N1) 2009 infection exhibited
HI titers of 1:80 or above (dashed dark line in figure 2), but only 11
of 23 children in this age group (47.8%, 95% CI: 33.5–66.5) who
reported vaccination with PandemrixH had HI titers $1:10, and
21.7% (95% CI: 12.0–40.4) had HI titers $1:40 (dark line). The
differences between HI titers in children aged 1 to 4 years after
natural infection and after vaccination were statistically significant
(Kolmogorov-Smirnov test for difference between two curves,
p-value: 0.003). For children aged 5 to 17 years no such statistically
significant difference (grey dashed line = natural infection; dotted
line= vaccinated) was observed (Kolmogorov-Smirnov test, p-value:
0.752).
In addition antibody titers in children vaccinated with Pandem-
rixH aged 1 to 4 years (dark black line) were significantly lower than
in vaccinated children aged 5 to 17 years (grey dotted line)
(Kolmogorov-Smirnov test, p-value: 0.0002). In contrast, after
natural infection higher titers were observed in the younger children
as compared to the older age group. The numbers, however, are
small and the difference was not statistically significant (Kolmo-
gorov-Smirnov test, p-value: 0.0941).
There appeared to be an inverse association between the
geometric mean HI titers against the A (H1N1) 2009 influenza
Table 3. History of infections and hemagglutination inhibition titers (HIT) in non-vaccinated children.
History of infections Diagnosis of A(H1N1)2009
Cumulative
missings*** Sum
HIT
No infection
reported*
One or more
infections**
Suspected by
physician
Virologically
confirmed
,1:10 n 168 424 21 0 87 700
Column% (95%CI) 56.0 (51.4–60.8) 59.1 (56.2–62.2) 23.6 (17.4–32.2) 0.00 (0.2–1.13) 49.4 (43.6–55.9)
1:10 or 1:20 n 41 95 23 5 33 197
Column% (95%CI) 13.7 (10.8–17.4) 13.2 (11.3–15.5) 25.8 (19.3–34.6) 20.0 (11.0–37.5) 18.8 (14.6–24.3)
.= 1:40 n 91 198 45 20 56 410
Column% (95%CI) 30.3 (26.3–35.0) 27.6 (25.0–30.5) 50.6 (42.5–59.7) 80.0 (67.0–91.8) 31.8 (26.6–38.1)
Total 300 717 89 25 176**** 1307
*‘‘Infection’’ was defined as any infection, since the clinical picture of flu in children may not be confined to typical symptoms of upper or lower respiratory tract
infection.
**without suspected or confirmed diagnosis of A (H1N1) 2009.
***Cumulative missing values in ‘‘history of infections’’ or/and ‘‘diagnosis of A (H1N1) 2009’’.
****There were 161 children with missing values for the variable ‘‘diagnosis of A (H1N1)’’ (no such diagnosis; suspected by physician; lab-confirmed) and an additional
19 children with missing values in ‘‘history of infections’’ (no infection; one or more infection) (see table 1). Four children had missing values regarding both variables,
therefore the total of missing values was 176 (161+1924 = 176).
doi:10.1371/journal.pone.0023955.t003
Figure 2. Reverse cumulative distribution curves of children vaccinated against the A (H1N1) 2009 virus ,5 years (n=23), .=5
years (n=78) and in children with laboratory-confirmed A (H1N1) 2009 infection ,5 years (n=6), .=5 years (n=19). Vaccinated
children and children with laboratory-confirmed A (H1N1) infection were mutually exclusive. Children vaccinated against the A (H1N1) 2009 virus
exhibit lower titers compared to children with laboratory-confirmed A (H1N1) 2009 infection. This can be observed in both age groups with greater
difference in younger children.
doi:10.1371/journal.pone.0023955.g002
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virus and previous vaccination with seasonal influenza vaccine. In
children vaccinated both with the seasonal and the pandemic
vaccine the OR for HI titers $1:40 was 0.68; 95% CI 0.46–1.01)
compared to children vaccinated with the pandemic vaccine
alone.
Discussion
Comparison of seroprevalence against influenza A (H1N1) 2009
in pre- and post-pandemic sera indicates that about a quarter of
the unvaccinated preschool (1–4 years) and almost half of the
unvaccinated school age children (5–17 years) were infected with
influenza A (H1N1) 2009 during the pandemic in Germany. A
titer of $1:40, usually considered ‘‘protective’’ (i.e. associated with
.50% reduction of the risk of contracting influenza) [10], was
observed in 23% of preschool and 36% of school age children,
taken together vaccinated and unvaccinated (figure 1). A history of
pandemic influenza vaccination was reported for ,7% of
participating children, a percentage similar to the existing estimate
of ,8% for persons .14 years in Germany [11]. HI titers $1:40
in as little as 22% of vaccinated children aged 1 to 4 years
approximately 4–8 months after vaccination point to a need for
further evaluation of the immune response to adjuvanted influenza
vaccines in young children although there is a possibility that this is
due to chance given that there were only 23 vaccinated children
and 6 children with lab-confirmed A (H1N1) 2009 infection ,5
years.
The incidence of A (H1N1) 2009 infections in children and
adolescents in Germany was similar to those reported from the
UK (after first wave) [2] and New Zealand [7], but somewhat
lower than after the second wave in UK [8]. As in these studies, we
found a considerably higher incidence of infections in school age
compared to preschool children, which also corresponds to the
reported age-specific incidence of infections from surveillance data
in Germany (unpublished data of the Robert Koch-Institute).
Approximately 25% of children with detectable antibodies
against A (H1N1) 2009 reported no history of any infectious
disease episode during the pandemic influenza season. Disease
history in our study is based on parents’ or participants’ recol-
lection over a period of several months and may therefore not be
fully reliable. It is likely that mild events of disease may not have
been recalled which would result in an overestimation of sub-
clinical infections. On the other hand, reported infection episodes
may have been unrelated to influenza A (H1N1) 2009, which
means the proportion of subclinical A (H1N1) 2009 infections
could have been even higher. In the study from New Zealand [7],
the proportion of subclinical infections was estimated as 45% (for
all ages). Smaller studies among contact persons of confirmed cases
found proportions of subclinical infections between 9% and 73%
[12–14].
In Germany the pandemic vaccine became gradually available
starting from the last week of October 2009. While two doses had
been recommended initially, the official vaccination recommen-
dation for children (as well as for adults) was changed from a two
dose to a single dose regimen as of December 14th 2009 [15]. The
vaccine used was an AS03B-adjuvanted split virus vaccine (3.75 mg
hemagglutinin) with a half dose recommended for children aged 6
months to 9 years. The lower antibody titers observed in our study
in young compared to older children after vaccination are unlikely
to be explained by chance. Differential misclassification of the
vaccination history against the pandemic influenza virus by the
children’s age is unlikely. Although we have not ascertained the
number of vaccine doses, most children had presumably received
one dose only, because by the time the second dose was due ($3
weeks after the first dose), a second dose was no longer recom-
mended. It remains unclear whether this vaccination regimen is the
reason for the lower antibody titers in the young children. Concern
regarding a possibly weaker immune response in young children has
also been raised for the non-adjuvanted pandemic influenza
vaccines [3,16]. Available evidence suggests high seroconversion
rates in young children after two doses of AS03B-adjuvanted split
virus vaccine (UK) [17] and possibly also after one dose (Spain) [18].
Clinical vaccine effectiveness, however, has been demonstrated
for one dose of the vaccine in persons$14 years and most recently
for children as well [19–21]. In young children, however, vaccine
effectiveness appeared to be lower than in adolescents and the
95% CI was wide [21].
For children who had been vaccinated with a seasonal vaccine
in previous years, titers after vaccination with the pandemic
vaccine were somewhat, but not significantly lower. A similar
finding was recently observed in a vaccine effectiveness study of
the AS03 adjuvanted influenza A (H1N1) 2009 vaccine for adults
[22,23].
This seroprevalence study was performed with an optimized in-
house hemagglutination inhibition test which gave clear and
highly reproducible results and allowed to determine titers of 1:10
against influenza virus A (H1N1) 2009. We decided not to use
a micro neutralization test in addition since the HIT is widely
accepted as reference test for detection of subtype-specific influenza
antibodies and the inter-assay and inter-laboratory reproducibility
and standardization is better for HIT than for micro neutralization
([24,25] and unpublished own data). Furthermore it has been shown
in multiple studies that there is a good overall correlation between
the results of the two assays for H1N1 [2,8,24].
Instead we optimized the HIT-SOP to reach a high specificity
without loosing relevant sensitivity. We found much fewer HIT
positive results in the pre-pandemic sera than other studies, where
arbitrary cutoffs of 1:32 or 1:40 had to be introduced [2,24,
26,27,28]. We detected only 12 of the 300 control sera repeatedly
positive for A (H1N1) 2009 influenza virus antibodies and only 2
in the younger age group of 1 to 4 years, while in the study group
all children with virologically proven pandemic A (H1N1) 2009
infection exhibited mainly high antibody titers. Additionally, in a
subsample of the control and study sera no correlation between
antibodies against seasonal A/Brisbane/59/2007(H1N1) and
antibodies against A (H1N1) 2009 influenza was found [28].
Therefore a simple cross reactivity at least between the antibodies
against these two H1N1 influenza viruses can be excluded [27].
The prevalence of antibodies against seasonal A H3N2 was very
low in sera from the study and control group (data not shown).
The external reference serum pool obtained from the National
Institute for Biological Standards and Control (NIBSC), with a
defined titer after multi-laboratory testing as 1:180, however,
absolutely reproducibly yielded a titer of 1:80 (i.e. practically one
twofold dilution lower) in our test. Although the titers determined
by our method are slightly lower (one twofold dilution) than
determined by other HIT-SOPs, we did not change our method
because we had no indication for false negative results and we
wanted to minimize false positive results.
In order to allow for a valid estimation of the incidence of A
(H1N1) 2009 during the 2009/2010 season we accepted only pre-
pandemic sera that were collected within 6 month before onset of
the A (H1N1) 2009 pandemic in Germany, thereby assuring that
the seasonal influenza virus A experience was as similar as possible
in both groups and that the relevance of waning antibody titers
was minimized. Within the age groups 1 to 4 and 5 to 17 years the
numbers of pre- and post-pandemic sera were collected propor-
tionally by age in order to assure structural homogeneity.
Pandemic Influenza A in German Children
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Serum samples from children attending medical care for
seroprevalence studies on pandemic influenza, as also used in a
recent study from the UK [2], may not be fully representative. A
population-based study in children with possibly higher represen-
tativity, however, might be fraught with selection bias in case
families with a presumed history of influenza A infection were
more likely to participate.
In conclusion, serologically determined incidence of influenza A
(H1N1) 2009 infections in children indicates overall high infection
rates, with older children (5–17 years) infected twice as often as
children between 1 and 4 years. In about a quarter of the children
with HI titers after the season 2009/2010 subclinical infections
must be assumed. Our study provides the first estimate of post-
pandemic population partial immunity in this age group in
Germany. The observed low HI titers in young children after
vaccination with the AS03B-adjuvanted split virion vaccine need
further scrutiny.
Methods
Serum and data collection
Eight German pediatric primary care hospitals (Bremen, Berlin,
Krefeld, Wuppertal, Erfurt, Wu¨rzburg, Mannheim, Mu¨nchen)
provided sera from April 1st to July 31st 2010 obtained during
blood withdrawal for routine laboratory testing from in- or
outpatients aged 1 to 17 years. Children with an illness impeding
an adequate immune response were excluded, so were children
with serious conditions. Eligible children and their parents were
informed about the study with age-adapted study descriptions and
asked for their written consent. The study was approved by the
Ethics Committee of the Bavarian Medical Association.
The following data were collected on a one-page questionnaire
filled in by the parents: age and sex of the child, history of
infectious disease episodes since June 2009, history of ‘‘swine flu’’
by physician’s tentative clinical diagnosis vs. laboratory-confirmed
diagnosis, history of pandemic or seasonal influenza vaccination,
and kindergarten/school attendance. Questionnaires were sent to
the study office in Munich and double-entered into a common
data base.
Minimum 400 ml serum samples were sent by cool pack to the
virological study laboratory in Ulm for determination of antibody
titers. Questionnaires and serum samples were labeled with
corresponding anonymous serial numbers. Laboratory staff was
not aware of the data collected on the serum donors. Serological
results and questionnaire data were linked after the end of the
serological testing only.
Pre-pandemic samples
300 control sera for the study were taken from the frozen stored
sera bank of the virological institute in Ulm, originally sent for
routine virological diagnostic. The sera were selected according to
two criteria: 1) the respective blood samples had to be collected
between November 2008 and April 2009 and 2) for the age groups
1 to 4 and 5 to 17 years the numbers of pre-pandemic sera were
proportionally to the age distribution of sera in the post-pandemic
study sample.
Laboratory procedures
For determination of the antibody responses an in-house
hemagglutination inhibition test (HIT) was established in Ulm to
minimize non-A (H1N1) 2009- specific results [11,24,29]. During
establishment of the HIT different buffers, protein additions, and
erythrocytes from different species in different concentrations and
receptor destroying enzymes (RDE) were evaluated [26].
The study and control sera were tested using the optimized HIT
standard operation procedure (SOP). To destroy non-specific
inhibitors of influenza virus hemagglutination sera were pretreated
with RDE (DENKA Seiken CO Ltd, Tokyo, Japan) [26]. RDE
was reconstituted with H2O and stored frozen in aliquots (100 ml).
Before usage RDE stock solution was diluted 1:20 in 0.9% NaCl.
50 ml Serum was mixed with 100 ml RDE and incubated 16–18 h
at 37uC. After inactivation 30 min at 56uC, 350 ml hepes saline
albumine (HSA, 0.14 M NaCl, 0.025 M hepes, 0.001 M
CaCl2+1%BSA (before usage), pH 6.2–6.3) was added (1:10
serum dilution). Two fold serial dilutions (25 ml) of sera were
performed using HSA+1% BSA in microtiter plates (round
bottom). Influenza-A virus antigens (pandemic A/California/7/
2009 (H1N1), seasonal A/Uruguay/716/2007 (H3N2), seasonal
A/Brisbane/59/2007 (H1N1), all GlaxoSmithKline, Dresden,
Germany) were diluted after HI pre-testing to obtain a solution
containing 4 hemagglutinating units (HU). After addition of 25 ml
antigen, shaking, and incubation (30 min, room temperature (RT))
50 ml newborn chicken erythrocytes (Laboratory Dr. Merk&Kol-
legen, Ochsenhausen, Germany) (0.5% in HSA) were added,
plates shaken again, incubated (2 h, RT) and read by 2
independent evaluators using a magnification lens (610). The
titer is defined as the highest serum dilution showing complete
inhibition of the agglutination of erythrocytes. A serum control for
every serum without addition of antigen and positive (1:80), low
positive (1:10) and negative (1:,10) control sera were included for
every test. An external reference serum pool was obtained from
the Health Protection Agency National Institute for Biological
Standards and Control (NIBSC), UK, and used to validate our
internal positive control sera. Test results were accepted if the back
titration of antigen revealed 4 HU and the control sera yielded
correct results. Sera showing non-specific hemagglutination were
tested again after absorption (1 h at 4uC) with 50 ml of 40%
newborn chicken erythrocyte suspension in HSA. For determina-
tion of sensitivity and specificity of our HIT we used the 300 pre-
pandemic sera (true negative) and 47 sera available from our
diagnostic laboratory at that time including 11 Ulm patients with
virologically proven pandemic A (H1N1) 2009 infection and 36
vaccinated co-workers (true positive). Sensitivity was 1.00 and
specificity 0.96 for titer $1:10. With 14 hemolytic study sera HI
titer could not be determined.
Statistical analysis
Reverse cumulative distribution curves were calculated to
compare proportions above different threshold hemagglutination
inhibition titers for unvaccinated children (by age groups 1–4 years
and 5–17 years and for children with laboratory-confirmed A
(H1N1) 2009 infection), for children vaccinated against A (H1N1)
2009 and for controls.
Logistic regression models were used to examine differences in
HI titers according to age, sex, region, history of infections since
June 2009, vaccination against seasonal influenza and kindergar-
ten/school attendance. Chi-square and Kolmogorov-Smirnov
tests were used to compare HI titers between different strata of
children.
To estimate the incidence of A (H1N1) 2009 infection during
the 2009/2010 pandemic in Germany we calculated the difference
between the proportion of sera with a HIT titer .1:10 in pre- and
post-pandemic samples. Additional evaluations were done using
an arbitrary cut-off of $1:40 titer, generally assumed to indicate
protection. Confidence intervals for the difference in proportion of
children achieving titers $1:10 and $1:40 pre-and post-pandemic
were calculated using the Newcombe-Wilson method [30].
All statistical analyses were done with SAS 9.2 and Excel 2003.
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